Teva Pharmaceutical Industries Limited · TASE:TEVA

Teva Pharmaceutical Industries — Barclays Capital Global Healthcare Conference 2011

17 slides from Teva Pharmaceutical Industries's conference presentation, Mar 16, 2011

  1. Slide 1: Barclays Capital Global Healthcare Conference

    Barclays Capital Global Healthcare Conference Jon Congleton, SVP & General Manager, Teva Neuroscience March 16, 2011 We make quality healthcare accessible around the world 1

  2. Slide 2: Forward-looking statements

    Forward-looking statements TODAY’S PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS, WHICH EXPRESS THE CURRENT BELIEFS AND EXPECTATIONS OF MANAGEMENT. SUCH STATEMENTS INVOLVE A NUMBER OF KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES THAT COULD CAUSE OUR FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS TO DIF

  3. Slide 3: Teva and Neuroscience

    Teva and Neuroscience  1970’s began work with coploymer-1  1995: Joint venture between Teva and Marion Merrell Dow established.  1997: Launched Copaxone in the U.S.  2001: Teva buys out JV.  2006: Launched Azilect in the U.S.  Staff:  “Big Pharma” talent throughout and deep knowledge of the M

  4. Slide 4: COPAXONE

    COPAXONE We make quality healthcare accessible around the world 4

  5. Slide 5: MS Market Space in the U.S.

    MS Market Space in the U.S. ~10,000 Treating Neuros Managed care rebates relatively constant Co-insurance 472,000 Share Payor Consolidation Total US MS Patients (est) “Donut Hole” ~25,000 Managed Medicaid Betaseron Patients Location 80,000 226,000 ~63,000 RRMS RRMS Avonex ~60,000 CIS CIS Patients Sp

  6. Slide 6: MS Situation Analysis

    MS Situation Analysis Competitive pressure in MS Market is Increasing  Branded competitors may double over five years  COPAXONE strengths to defend leadership position include:  Teva reputation, Patient database asset, Established access and support systems, Proven long-term efficacy and safety w

  7. Slide 7: IMS TRx Market Share 2010

    IMS TRx Market Share 2010 45% 40% 35% 30% 25% 20% 15% 10% 5% 0% Jan-10 Feb Mar Apr May June July Aug Sept Oct Nov Dec Jan '11 Avonex COPAXONE Betaseron Rebif Tysabri Extavia Gilenya IMS Monthly MS Topline Report, January 2011 We make quality healthcare accessible around the world 7

  8. Slide 8: IMS TRx Volume

    IMS TRx MS Volume 2010 vs 2009 IMS TRx Volume Difference 2010 vs 2009 40,000 30,000 20,000 IMS TRx Volume 10,000 - Avonex COPAXONE Betaseron Rebif Tysabri Extavia Gilenya (10,000) (20,000) (30,000) We make quality healthcare accessible around the world 8

  9. Slide 9: Evolving MS Market Dynamics

    Evolving MS Market Dynamics COPAXONE and Laquinimod will Compete in a More Complex Environment Cladribine ??? Betaseron® Tysabri® (IFNβ-1b) (natalizumab) ® Campath® Avonex Extavia® (alemtuzumab) (IFNβ-1a) (IFNβ-1b) COPAXONE® Laquinimod (glatiramer acetate injection) Fingolimod (FTY720) Fumarate Nova

  10. Slide 10: COPAXONE Development and Investment

    COPAXONE Development and Investment GALA  Three times a week Copaxone  Rapid trial enrollment  Anticipate closure of trial and data mid-2012  Potential market entry mid to late 2013 Copaxone 0.5ml  Feedback received from FDA on initial filing  Need for clinical data requested from the agency 

  11. Slide 11: Laquinimod

    Laquinimod We make quality healthcare accessible around the world 11

  12. Slide 12: Laquinimod Market Opportunity

    Laquinimod Market Opportunity 472,000 Total US MS Patients (est) ~25,000 Betaseron Patients Value of 27,000 Naïve 80,000 226,000 ~63,000 $2B if RRMS RRMS Avonex IFN conversion 53,000 Previous CIS CIS Patients treated Copaxone at risk 222,000 of DC 250,000 ~100,000 101,000 Not on 17,000 Treated COPAX

  13. Slide 13: Laquinimod

    Laquinimod  Laquinimod is a novel and promising oral, once-daily, small molecule immunomodulator (SMI) with a differentiated mechanism of action  In ALLEGRO, laquinimod achieved primary and secondary endpoints, demonstrating a significant positive impact on disease activity, neurodegeneration and

  14. Slide 14: Laquinimod Timeline

    Laquinimod Timeline FDA Submission Of Laquinimod ALLEGRO Trial BRAVO Trial FDA Approval Announcement Announcement Potential ECTRIMS ALLEGRO Presentations Laquinimod Data Results AAN ALLEGRO & AAN 2012 2011 BRAVO Q4 ‘10 Q1 ‘11 Q2 ‘11 Q3 ‘11 Q4 ‘11 Q1 ‘12 Q2 ‘12 We make quality healthcare accessible a

  15. Slide 15: Azilect

    Azilect We make quality healthcare accessible around the world 15

  16. Slide 16: Parkinson's Situation Analysis

    Parkinson’s Situation Analysis Market Conditions  Top attributes for selecting a PD therapy are:  Slows progression , Effective for motor symptoms, Improves ADL, Safe & Convenient  Competitive PD brands promotional presence has diminished  PD Rx volume is 85% generic  Mirapex, Requip, Stalevo a

  17. Slide 17: Azilect

    Azilect  Indicated as initial therapy and as adjunctive at first signs of wearing “off” with other PD therapies  Extensive clinical profile  Potential for disease modification as seen in TEMPO and ADAGIO  Safe, well tolerated and convenient Promoted Brand PD Therapies 35,000 30,000 25,000 Mirape

Teva Pharmaceutical Industries — Barclays Capital Global Healthcare Conference 2011 on 6ix